Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

XBiotech releases additional analysis of MABp1 study
March 2018
SHARING OPTIONS:

AUSTIN, Texas—In late January, XBiotech Inc. shared further data analysis of its Phase 2 study of its True Human antibody MABp1 as a treatment for hidradenitis suppurativa. The study’s primary endpoint was reached, with significant treatment benefit seen using the HiSCR endpoint. Other methods for assessing disease severity and response to treatment have been suggested, and the Phase 2 study data is now being evaluated with the iHS4 scoring system to see how it compares with the HiSCR results. The newly presented data consist of a retrospective analysis using the iHS4 score for 20 patients randomized to receive placebo or MABp1 therapy. Approximately 30-percent decrease of the iHS4 score from baseline at week 12 coincided with 100-percent sensitivity for positive HiSCR score. The change was found in one and four patients randomized to placebo and MABp1, respectively.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.